Navigation Links
AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
Date:6/16/2009

    GAI-122, an investigational injectable nano-emulsion formulated with
    AlphaRx's proprietary drug delivery technology, provides significant
    neuroprotection in animal behavioral models. Gaia BioPharma plans to
    initiate a clinical development program to further study GAI-122 for an
    acute and as yet, unmet neurological indication.

MARKHAM, ON, June 16 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited, a privately held, early stage biopharmaceutical company focused on hospital-based injectable therapeutics, are pleased to provide a progress report on GAI-122.

GAI-122 offers significant and direct neuroprotection in both in vitro and in vivo ischemic conditions. Experimental evidence suggests that the neuroprotective action of GAI-122 is related to its' active inhibition of apoptosis or cell death. GAI-122 shows potential as a major treatment innovation in the management of ischemic neurological disorders such as stroke and traumatic brain injury.

The proposed initial indication for GAI-122 is an acute neurological disorder affecting millions of patients undergoing cardiac and hip replacement surgery. It is estimated that the market potential for this unmet indication exceeds US$2 billion a year.

GAI-122 is in the final stage of formulation optimization, which is expected to be completed by the end of summer 2009, proceeding to clinical trial materials manufacturing thereafter. GAI-122 is protected by 4 US patent applications.

In October 2008, AlphaRx licensed GAI-122 to Gaia BioPharma. Under the terms of the amended agreement, AlphaRx is eligible to receive milestone payments of up to $50 million for the successful development and commercialization of GAI-122, as well as royalties on worldwide sales. In addition, Gaia BioPharma has assumed all development costs.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical compa
'/>"/>

SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. AlphaRx Signs Cooperative Research and Development Agreement with US Army
2. AlphaRx Provides Corporate and Development Update
3. AlphaRxs Indaflex(TM) Continues its Clinical Development
4. AlphaRx CEO Accumulates More Company Shares
5. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
6. AlphaRx Announces Debt Conversion
7. AlphaRx To Present at 47th Annual ICAAC
8. PDL BioPharma Announces Record Date for October 1 Dividend Payment
9. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
10. SAFE-BioPharma Webinar Featuring ARX's Digital Signatures Combined with Microsoft SharePoint for Bio-Pharma industry
11. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/21/2014)... offers a wide range of women’s dresses, fashionable accessories ... BellasDress Christmas Sale , offering big discounts on all ... a famous online supplier of women’s dresses; it always ... promotions. The dress experts of the company provide professional ... of offering high quality wedding dresses and women’s special ...
(Date:12/21/2014)... HealthDay Reporter FRIDAY, Dec. 19, 2014 ... than traditional cigarettes, new research finds. Even though ... thousands of ex-smokers said they have fewer cravings and are ... to smoke, researchers reported. "The pattern was ... use than for tobacco use," said lead researcher Jonathan Foulds, ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Parker & ... of heating, cooling, plumbing and other similar home contractor ... 2014 with regard to its expert contracting services. The ... leader that has been serving Arizona for well over ... providing the absolute best in quality customer service to ...
(Date:12/21/2014)... Vancouver, WA (PRWEB) December 21, 2014 CannabisClassifieds.com ... website redesign. The only one of its kind, the ... to find local marijuana for 14 years running. It ... Angie’s List to make cannabis readily available to the masses. ... way to grasping the golden ring of public approval. ...
(Date:12/20/2014)... December 21, 2014 MissyDress, a distinguished ... all prom lovers. The business has drastically cut prices ... dresses to everyone until Jan. 30, 2015. Many of ... sweetheart dresses, V-neck dresses, lace dresses, and more. , ... not there every day. Whether A-line princess prom dresses ...
Breaking Medicine News(10 mins):Health News:BellasDress.com Announces its BellasDress Christmas Sale 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
... believe they have found a gene that predisposes people to ... 262 families with alcoholic members all were assessed for three ... been linked to alcoholism. ,Results showed one of ... risk. Researchers aren’t sure how the gene predisposes someone to ...
... required for success in school are similar to those ... that one’s cognitive abilities predict success in the academic ... believe what is needed for job success is different ... the University of Illinois tested whether abilities related to ...
... has been the only treatment for a deteriorated hip joint. ... the traditional replacements.// ,Bobby Castor plays on his school’s ... to a condition called avascular necrosis. Decreased blood flow caused ... golf swing, it hurt Castor’s game. “I was just limping ...
... have steadily increased their consumption of chicken from 32 ... 81 pounds per person in 2000. ,A new study ... than other poultry or meat. Arsenic is an approved ... parasites in chickens. ,Researchers from the National Institutes ...
... drug that strongly activates certain systems in the brain.// ... is often addictive. According to the 2000 National Household ... the United States have tried methamphetamine at least once ... methamphetamine users and 18 healthy people to determine how ...
... that infects and destroys T-cells in the immune system. ... there are between 800,000 and 900,000 people living with ... less likely to be infected with HIV, and a ... from nine specimens of human foreskin. They found each ...
Cached Medicine News:
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... Registreer nu via  http://bit.ly/ag8Sypm14de ... Februar sind alle akkreditierten pharmazeutischen Patientenversorgungsakten-Firmen (PMR) ... PROGRAMM ™ 2015 in Amsterdam ... Tagung soll dazu beitragen, der Aegate PMR ... profitablen Unternehmensdienstleistungen, die für Apotheken und die ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the ... a company overview at J.P. Morgan,s 29th Annual Healthcare Conference ... the Westin St. Francis Hotel in San Francisco, CA. ... be available on the "Investors & Media" section of the ...
... Mass., Jan. 6, 2011 Saints Medical Center, a ... is pleased to announce it has entered into a ... ZOLL ) of Chelmsford, Mass., a leader in comprehensive ... Saints-based EMS service working with ZOLL to collaborate on ...
Cached Medicine Technology:Isis Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement 2Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement 3
Ultra-fine 5 mm tying platform is valuable when manipulating delicate 10-0 and 11-0 sutures. Pin in handle keeps tips in alignment. Shafts available straight or angled 45 degrees, 8 mm from tip. Stra...
Angled 45 degree shafts with tying platform. Wide serrated handle with dull finish. Overall length 4.2 inches....
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Curved shafts. Overall length 3.9 inches....
Slightly curved 10 mm jaws and serrated cross action handle with polished finish. Overall length 4.6 inches....
Medicine Products: